Clinical Trials Sponsored by Atreus Pharmaceuticals Corporation

Total 235 results

Acerus Pharmaceuticals Corporation

Completed

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Female Orgasmic Disorder

United States, Canada, Australia
Acerus Pharmaceuticals Corporation

Completed

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Recruiting

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women

Female Sexual Dysfunction

United States
Acerus Pharmaceuticals Corporation

Completed

Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ (MyT)

Hypogonadism

Canada
Acerus Pharmaceuticals Corporation

Completed

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

Male Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy of an Intranasal Testosterone Product

Hypogonadism

United States
Acerus Pharmaceuticals Corporation

Withdrawn

Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma

Asthma
Acerus Pharmaceuticals Corporation

Withdrawn

Influence of Administration Route of Testosterone on Male Fertility

Hypogonadism

Netherlands
Advanced Accelerator Applications
Atreus Pharmaceuticals Corporation

Completed

99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers

Healthy Adult Volunteers

Canada
Acerus Biopharma Inc.

Terminated

Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

Hypogonadism

United Kingdom
University of Miami
Acerus Pharmaceuticals Corporation

Completed

A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections

Hypogonadism, Male

United States
University of Miami
Acerus Pharmaceuticals Corporation

Completed

Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters

Hypogonadism, Male

United States
University of Utah
Acerus Pharmaceuticals Corporation

Withdrawn

Natesto Testosterone Nasal Gel for Hypogonadal Men

Sexual Dysfunction | Erectile Dysfunction

United States
Atrium Medical Corporation

Completed

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension (ARTISAN)

Hypertension, Renovascular | Renal Artery Stenosis

United States
Atrium Medical Corporation

Completed

The INFUSE - Anterior Myocardial Infarction (AMI) Study

Acute Anterior Myocardial Infarction

United States, Germany, United Kingdom, Austria, Netherlands, Poland
Atrium Medical Corporation

Terminated

COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1) (CONFIRM 1)

Coronary Artery Disease

Belgium
Atrium Medical Corporation

Completed

Atrium iCAST Iliac Stent Pivotal Study (iCARUS)

Peripheral Vascular Disease

United States, Germany
Atrium Medical Corporation

Terminated

The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries (VANTAGE-1)

Coronary Artery Disease

New Zealand
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

Asthma
Nephron Pharmaceuticals Corporation

Completed

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Biotest Pharmaceuticals Corporation

Withdrawn

Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation (Nabi-HB-SC)

Hepatitis B, Chronic
Adamis Pharmaceuticals Corporation

Unknown

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Prostate Cancer

United States
Inotek Pharmaceuticals Corporation

Completed

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Inotek Pharmaceuticals Corporation

Completed

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

Health

United States
Inotek Pharmaceuticals Corporation

Completed

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Acute Myocardial Infarction

United States, Israel
Atrium Medical Corporation

Completed

Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta

Coarctation of the Aorta

Israel, Australia, Brazil, Canada, Germany, Italy, United Kingdom
Atrium Medical Corporation

Completed

ClearWay™ RX Registry Trial

Heart Diseases | Vascular Diseases

United States
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (COURSE)

Venous Thromboembolism

Poland, Bulgaria, Latvia, Lithuania, Ukraine
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

Asthma
Biotest Pharmaceuticals Corporation

Completed

Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

Hepatitis B Virus Associated Liver Disease

United States
Inotek Pharmaceuticals Corporation

Completed

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

Ocular Hypertension (OHT) | Primary Open-Angle Glaucoma (POAG)

United States
Inotek Pharmaceuticals Corporation

Completed

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension (OHT) | Primary Open-Angle Glaucoma (POAG)

United States
Biotest Pharmaceuticals Corporation

Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Liver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | Viruses

United States
Adamis Pharmaceuticals Corporation

Terminated

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Covid19

United States
Inotek Pharmaceuticals Corporation

Completed

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma (MATrX-1)

Ocular Hypertension (OHT) | Primary Open-Angle Glaucoma (POAG)

United States
Inotek Pharmaceuticals Corporation

Terminated

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

Heart Diseases | Postoperative Complications

United States, Israel, Australia, India
Advancis Pharmaceutical Corporation

Completed

APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat

Tonsillitis | Pharyngitis

United States
Advancis Pharmaceutical Corporation

Completed

APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat

Tonsillitis | Pharyngitis | Sore Throat

United States, Canada
Advancis Pharmaceutical Corporation

Completed

APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat

Pharyngitis

United States
Riverside Pharmacueticals Corporation

Completed

Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)

Other

Canada
Novelwise Pharmaceutical Corporation

Recruiting

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Malignant Neoplasm | Malignant Neoplasm of Brain

Taiwan
Medicis Pharmaceutical Corporation

Completed

A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.

Human Volunteer

United States
AbbVie
Endo Pharmaceuticals; Allergan Sales, LLC; Acerus Pharmaceuticals Corporation; Upsher-Smith...

Completed

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE)

Cardiovascular Diseases | Hypogonadism

United States, Puerto Rico
Biotest Pharmaceuticals Corporation
Biotest

Completed

BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma

Multiple Myeloma

United States
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Biotest Pharmaceuticals Corporation
Biotest

Completed

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Biotest Pharmaceuticals Corporation
Biotest

Completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States

3

Subscribe